文献速递类风湿关节炎

类风湿关节炎的分类:是时候修订标准了吗?

Classification of rheumatoid arthritis: is it time to revise the criteria?
PubMed 文献 · RMD Open · 2024-04-19

本文讨论2010年ACR/EULAR类风湿关节炎分类标准在早期识别与误分类风险之间的平衡,指出类风湿因子与抗瓜氨酸化蛋白抗体被赋予相同权重,而后者特异性更高,低滴度类风湿因子可能导致误分类及不恰当的改善病情抗风湿药治疗,并提出是否应修订标准以提高特异度和敏感度。

要点

  • 2010年ACR/EULAR标准能识别多数早期无影像学改变的类风湿关节炎患者。
  • 与1987年ACR标准相比,2010年标准误分类风险更高,后者对早期类风湿关节炎敏感性明显较低。
  • 类风湿因子与抗瓜氨酸化蛋白抗体在2010年标准中权重相同,可贡献分类所需评分的最高50%。

核心结论

  • 2010年ACR/EULAR分类标准可识别多数尚无影像学改变的早期类风湿关节炎患者,但误分类风险高于1987年ACR标准。
  • 类风湿因子与抗瓜氨酸化蛋白抗体权重相同,而类风湿因子特异性中等,低滴度时尤甚,可能导致类风湿因子阳性患者误分类及不恰当的改善病情抗风湿药治疗。
  • 作者提出是否应更新标准以适应过去二十年的发现以提高特异度和敏感度。

研究设计与样本

  • 本文为针对类风湿关节炎分类标准的讨论性文章,未报告系统检索范围或样本量。

主要发现

  • 2010年ACR/EULAR标准能识别多数早期尚无影像学改变的类风湿关节炎患者,这些患者也可从早期使用改善病情抗风湿药治疗中获益。
  • 1987年ACR标准对早期类风湿关节炎的识别敏感性明显较低。
  • 2010年ACR/EULAR标准中类风湿因子与抗瓜氨酸化蛋白抗体权重相同,可贡献分类所需评分的最高50%。
  • 抗瓜氨酸化蛋白抗体被证明是类风湿关节炎最特异的血清学标志物,而类风湿因子特异性中等,低滴度时尤甚。

关键数值与推荐

  • 2010年ACR/EULAR分类标准中类风湿因子与抗瓜氨酸化蛋白抗体权重相同,可贡献分类所需评分的最高50%。
  • 抗瓜氨酸化蛋白抗体被证明是类风湿关节炎最特异的血清学标志物,类风湿因子特异性中等,低滴度时尤甚。

临床怎么用

  • 分类标准并非用于诊断,但在临床实践中常被用于支持诊断过程,包括临床决策。
  • 作者提出是否应更新标准以适应过去二十年的发现以提高特异度和敏感度。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Classification criteria have been developed for rheumatoid arthritis (RA) and other rheumatic diseases in order to gather a homogeneous patient population for clinical studies and facilitate the timely implementation of therapeutic measures. Although classification criteria are not intended to be used for diagnosis, they are frequently used to support the diagnostic process in clinical practice, including clinical decision-making. The 2010 American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) classification criteria for RA are capable of identifying the majority of symptomatic patients with RA already in the earliest stages of the disease who are not yet showing radiographic changes. These patients will also profit from the early implementation of therapy with disease-modifying antirheumatic drugs (DMARDs). However, the risk of misclassification is higher as compared with the former 1987 ACR criteria, which were considerably less sensitive to the recognition of patients with early RA. Of note, the presence of rheumatoid factors (RFs) and anticitrullinated protein antibodies (ACPAs) has been attributed equal weight in the 2010 ACR/EULAR criteria and may contribute up to 50% of the score needed for being classified as RA. However, while ACPAs have been proven to be the most specific serological markers of RA, the specificity of RF is moderate, especially at lower titres. This may lead to the misclassification of RF-positive patients and, consequently, the unjustified implementation of DMARD therapy. Therefore, issues arise on how comprehensive the criteria should be and whether they should be updated and adapted to findings from the past two decades that might increase both their specificity and sensitivity.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Steiner G, Verschueren P, Van Hoovels L, et al. Classification of rheumatoid arthritis: is it time to revise the criteria? RMD Open. 2024. PMID: 38642926. doi:10.1136/rmdopen-2023-003851

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。